Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

IF 2.3 4区医学 Q2 HEMATOLOGY Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI:10.1080/17474086.2024.2389993

Jacqueline F Wang, Yucai Wang

{"title":"Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.","authors":"Jacqueline F Wang, Yucai Wang","doi":"10.1080/17474086.2024.2389993","DOIUrl":null,"url":null,"abstract":"Introduction: Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma that is generally considered incurable. Covalent BTK inhibitors (cBTKi) are the cornerstone of treatment for relapsed or refractory (R/R) MCL, but treatment options are limited and prognosis is poor after cBTKi failure. Pirtobrutinib is a non-covalent BTK inhibitor that has demonstrated excellent efficacy and safety and represents an important new treatment in the evolving treatment landscape of R/R MCL.Areas covered: This review will provide an overview of the therapeutic landscape of R/R MCL, characteristics of pirtobrutinib, and efficacy and safety data of pirtobrutinib in R/R MCL from pivotal clinical trials. PubMed and major hematology conference proceedings were searched to identify relevant studies involving pirtobrutinib.Expert opinion: For patients with R/R MCL that has progressed after treatment with cBTKi, pirtobrutinib is an important and efficacious treatment that confers favorable outcomes. In the post-cBTKi setting, when chimeric antigen receptor (CAR) T-cell therapy is not available or feasible, pirtobrutinib is the preferred treatment for R/R MCL. How to sequence or combine pirtobrutinib with CAR T-cell therapy and other available or emerging therapies requires further investigation. Future studies should also explore the role of pirtobrutinib in earlier lines of therapy for MCL.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"651-659"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2024.2389993","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma that is generally considered incurable. Covalent BTK inhibitors (cBTKi) are the cornerstone of treatment for relapsed or refractory (R/R) MCL, but treatment options are limited and prognosis is poor after cBTKi failure. Pirtobrutinib is a non-covalent BTK inhibitor that has demonstrated excellent efficacy and safety and represents an important new treatment in the evolving treatment landscape of R/R MCL.

Areas covered: This review will provide an overview of the therapeutic landscape of R/R MCL, characteristics of pirtobrutinib, and efficacy and safety data of pirtobrutinib in R/R MCL from pivotal clinical trials. PubMed and major hematology conference proceedings were searched to identify relevant studies involving pirtobrutinib.

Expert opinion: For patients with R/R MCL that has progressed after treatment with cBTKi, pirtobrutinib is an important and efficacious treatment that confers favorable outcomes. In the post-cBTKi setting, when chimeric antigen receptor (CAR) T-cell therapy is not available or feasible, pirtobrutinib is the preferred treatment for R/R MCL. How to sequence or combine pirtobrutinib with CAR T-cell therapy and other available or emerging therapies requires further investigation. Future studies should also explore the role of pirtobrutinib in earlier lines of therapy for MCL.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估皮罗替尼治疗复发或难治套细胞淋巴瘤的疗效。

简介套细胞淋巴瘤（MCL）是一种不常见的非霍奇金淋巴瘤，通常被认为无法治愈。共价BTK抑制剂（cBTKi）是治疗复发或难治性（R/R）MCL的基石，但cBTKi治疗失败后，治疗选择有限且预后较差。Pirtobrutinib是一种非共价BTK抑制剂，已显示出卓越的疗效和安全性，是R/R MCL不断发展的治疗领域中的一种重要新疗法：本综述将概述R/R MCL的治疗前景、皮尔曲替尼的特点以及关键临床试验中皮尔曲替尼治疗R/R MCL的疗效和安全性数据。检索了PubMed和主要血液学会议论文集，以确定涉及吡咯替尼的相关研究：对于经cBTKi治疗后病情进展的R/R MCL患者，吡咯替尼是一种重要而有效的治疗方法，可带来良好的治疗效果。在cBTKi治疗后，当嵌合抗原受体（CAR）T细胞疗法不可用或不可行时，皮罗替尼是治疗R/R MCL的首选疗法。如何将 pirtobrutinib 与 CAR T 细胞疗法及其他可用或新兴疗法进行序贯或联合治疗还需要进一步研究。未来的研究还应探讨皮罗替尼在MCL早期治疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.